Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly

Herbert A. Schmid, Thierry Brue, Annamaria Colao, Mônica R. Gadelha, Ilan Shimon, Karen Kapur, Alberto M. Pedroncelli, Maria Fleseriu

Research output: Contribution to journalArticlepeer-review

53 Scopus citations


The purpose of this study was to gain more insight into the mechanism of action of pasireotide in patients who completed the PAOLA study. PAOLA was a 24-week, Phase III, randomized, three-arm study of pasireotide LAR 40 and 60 mg versus octreotide LAR 30 mg or lanreotide Autogel 120 mg in patients with inadequately controlled acromegaly. The current work was a planned exploratory objective of the PAOLA study that evaluated changes in levels of growth hormone (GH), insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBP-2, IGFBP-3), glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) in each treatment arm. Responders to pasireotide LAR (mean GH levels <2.5 μg/L and normal IGF-1 levels at 24 weeks) had lower GH and IGF-1 levels at baseline (GH 5.1 ng/mL, IGF-1 519 ng/mL) than non-responders (GH 7.9 ng/mL, IGF-1 672 ng/mL). Frequency of hyperglycaemia after pasireotide treatment was similar in responders and non-responders and depended more on the baseline FPG level. 47 % of all patients treated with pasireotide LAR (40 or 60 mg) did not receive antidiabetic medication at any time during this study. This is the first study to evaluate the treatment effect of pasireotide on key hormonal and glycaemic biomarkers and to identify potential predictors of pasireotide-associated hyperglycaemia. Pre-treatment glucose status may be predictive of the development of pasireotide-associated hyperglycaemia. A large subset of patients with acromegaly does not experience major disturbances in glucose homeostasis while receiving pasireotide LAR.

Original languageEnglish (US)
Pages (from-to)210-219
Number of pages10
Issue number1
StatePublished - Jul 1 2016


  • Acromegaly
  • Glucose
  • HbA
  • Hyperglycaemia
  • Pasireotide

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly'. Together they form a unique fingerprint.

Cite this